Frequently, drug development has focused on minute agents, but amino acid collaborations are rapidly demonstrating traction. This new strategy involves combining peptidic sequences with complementary medicinal modalities to tackle intricate condition mechanisms. By employing the specific properties of peptides – such as significant precision and